

Neuland Laboratories Limited

Investor Presentation
Q2FY25 & H1FY25

SAFE HARBOUR

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Table of Content





Q2FY25 & H1FY25 Highlights



SUCHETH DAVULURI

“The numbers of this quarter are subpar relative to how the business has been performing over the last few quarters. However, they are in line with our commentary right at the beginning of the year as to how we see FY25 panning out. The inherent uneven nature of our business means that annual progression is a better indicator of the company’s prospects than quarterly performance. We continue to make progress on our strategic plans and are enthusiastic about sustainable long-term growth driven by customer acquisitions, deepening capabilities, agile capacity expansion and optimization of processes.”

SAHARSH DAVULURI

“The revenues this quarter were driven by a few key molecules on the commercial CMS and GDS specialty side. Completion of additional manufacturing facilities in this year coupled with anticipated commercial launch of molecules on the CMS side gives us the confidence of achieving high growth in FY26 and beyond. We believe that the environment remains favourable for us in the medium to long term as indicated by customer interest and addition of early-stage projects.”



Business and Financial Highlights



H1FY25 Business and Financial Highlights

CMS

CMS revenues driven by commercial molecules.
Increasing interest from Biotech leading to increase in early-stage projects

GDS

Specialty business driven by Paliperidone
In Prime segment Mirtazapine, Levetiracetam, Escitalopram and Ezetimibe were the key molecules

Free Cash Flow (FCF) generation and utilisation

Generated Free Cash Flow of Rs. 45.8 crores during H1FY25, partly utilised in term loan repayment of Rs 17.1 crores
Capex Investment of Rs. 103.5 crores




Working Capital

Working capital days of sale at 112 days as against 107 days in Q1 FY25, Mainly on account of increase in inventory days


Q2FY25 Financial Highlights




**Total Income
(Rs. Cr)**




**EBITDA
(Rs. Cr)**



**PAT*
(Rs. Cr)**



**EPS
(Rs.)**




Financial Highlights

- Total Income for Q2FY25 at Rs. 315.2 crore (-25.1% YoY)
- EBITDA for Q2FY25 at Rs. 65.7 crore (-53.2% YoY)
- EBITDA Margin for Q2FY25 at 20.8% (decreased by 1260 bps YoY)
- PAT for Q2FY25 at Rs. 32.0 crore (-64.1% YoY)*
- Net Debt stood at Rs. (94.3) crore as at Q2FY25 end compared to Rs. (39.2) crore as at Q2FY24 end and Rs (110.2) crore as at Q1FY25 end

*Q1FY25 Includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

H1FY25 Financial Highlights



Financial Highlights


- Total Income for H1FY25 at Rs. 759.6 crore (-3.3% YoY)
- EBITDA for H1FY25 at Rs. 194.3 crore (-18.9% YoY)
- EBITDA Margin for H1FY25 at 25.6% (decreased by 490 bps YoY)
- PAT for H1FY25 at Rs. 130.3 crore (-13.9% YoY)*
- Net Debt stood at Rs. (94.3) crore as at H1FY25 end compared to Rs. (39.2) crore as at H1FY24 end

*H1FY25 Includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores


Key Balance Sheet Metrics




Current Ratio(x)




ROCE (%)



Fixed Asset Turnover (x)



Debt to Equity (x)






Particulars (Rs Cr)	Mar-21	Mar-22	Mar-23	Mar-24	Sep-24
Shareholder's Funds	781.9	835.6	988.4	1,276.5	1,388.5
Net Debt*	152.1	212.0	62.9	-32.6	-94.3
Tangible Assets (including CWIP and Investment property)	437.9	497.2	511.2	575.4	670.0**
Working Capital	308.6	376.9	463.0	525.4	464.1

*Net debt includes investment in Mutual Fund

**Investment property is re-classified as Assets classified as held for sale – Rs 14.0 cr in Sep-24

Key Operating Metrics Q2FY25



- Steady shift from low margin Prime to high margin Specialty and CMS segments
- CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers
- Specialty segment works on complex products and technologies, hence has a focused approach towards select customers


*Q1FY25 Includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

Key Operating Metrics H1FY25




Segment Revenue

■ Prime ■ Specialty
■ CMS ■ Others




Top 10 & Top 5 Products

■ Top 10
■ Top 5



Top 10 & Top 5 Customers



■ Top 10
■ Top 5



- Steady shift from low margin Prime to high margin Specialty and CMS segments
- CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers
- Specialty segment works on complex products and technologies, hence has a focused approach towards select customers

*Q1FY25 Includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

CMS – Revenue Split & Number of Active Projects



No. of active CMS projects

Q2FY25	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg*	Commercial	Total
API	10	10	11	3	7	9	50
Intermediate	10	7	10	4	6	10	47
Grand Total	20	17	21	7	13	19	97

Q2FY24	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	12	6	12	3	9	8	50
Intermediate	6	4	8	4	6	11	39
Grand Total	18	10	20	7	15	19	89

Q2FY23	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	16	4	7	6	7	9	49
Intermediate	10	6	2	1	7	12	38
Grand Total	26	10	9	7	14	21	87

Q2FY22	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Total
API	15	3	8	4	10	7	47
Intermediate	7	5	2	0	8	11	33
Grand Total	22	8	10	4	18	18	80

- Pre-clinical to P-3: Neuland generates revenue by process research & development as well manufacturing quantities for clinical trials
- *Pre-Reg/Reg: Phase-3 complete; Molecules filed but not yet commercial (Earlier labelled as 'Development') or where customer working towards adding Neuland as a second source for a commercial molecule
- Commercial: Neuland generates revenues by manufacturing APIs for commercial novel molecules for innovators
- Steady trend in molecules transitioning from clinical phases to commercialisation resulting in increase in revenue from commercial products



Company Overview

Company Overview



Established in

1984

40 years in API manufacturing and development



Total reactor volume of

941,000 Liters



~1700

Employees, 360
Scientists in R&D



Facilities Inspected by USFDA, EMA, PMDA, Rx-360, TGA, KFDA, ANVISA, WHO



Supported 3 NDA filings and 18 IND filings by supplying APIs and CMC documentation

Commercially Manufactured novel APIs and Intermediates for brands



Expertise in manufacture of Deuterated molecules, Cyanation, Solution and Solid phase peptides.

Cyclic peptides and PEGylated peptides, Hydrogenation, Bromination, Chiral molecules manufacture, Cryogenic reactions, Enzymatic reactions, Synthetic portion of fermented molecules, Micronization (D90 <5 micron)



3 cGMP Manufacturing facilities

Chemical R&D Labs


Peptide Labs

Analytical R&D Labs

Process Safety Labs

Hydrogenation Lab

Key Facts



Board Of Directors



**Dr. Davuluri
Rama Mohan Rao**
Executive Chairman




D. Sucheth Rao
Vice Chairman &
Chief Executive
Officer



D. Saharsh Rao
Vice Chairman &
Managing Director



**Dr. Christopher M.
Cimarusti**
Non-executive
Director



**Ms. Pallavi Joshi
Bhakru**
Independent
Director



Ms. Nirmala Murthy
Independent
Director



**Mr. Homi Rustam
Khusrokhhan**
Independent Director



**Mr. Prasad
Raghavan Menon**
Independent
Director



Mr. Sugata Sircar
Independent Director


Key Milestones

Our Journey




Successfully cleared 17 USFDA inspections

Multiple audits passed with Zero observations



Our Global Presence*



Manufacturing and Development partner to customers in over 80 Countries globally

* - Based on End-Market revenues – H1 FY25

Manufacturing Facilities Overview



UNIT - I

Bonthapally, Hyderabad 239 kL



UNIT - II

Pashamylaram, Hyderabad 381 kL



UNIT - III

Gaddapotharam, Hyderabad 321 kL



Year of Establishment

1986

1994

2017



Blocks

Block - 1, 2, 3, 4, H, kL & S

Block-1, 2, 3, FC, NMSM, Mini plant(A&B)

Block - 1, 2, 4, 5, 7 & 8



Hydrogenation Reaction Volume

7.5 kL

6 kL

5 kL



Solvent Recovery System

100 kL/D

20 kL/D

50 kL/D



Cryogenic Reaction Volume

25 kL

17 kL

15 kL



Regulatory

USFDA, EDQM, CFDA, PMDA, Et al.

USFDA, EDQM, PMDA, ANVISA, Et al.

Desktop Inspection by USFDA in 2020;
USFDA May 2023, ANVISA (Brazil) 2022

Adding capacities for backward integration and new business

State-of-the-art R&D Centre



Infrastructure

- 15 Development Labs with space for expansion
- 70 Fume hoods
- Analytical Labs
- Dedicated Kilo Lab for Scale up
- Dedicated Labs for Peptides
- Approvals for DSIR, Govt. of India and USFDA
- R&D Team of 360 People
- 600 MHz NMR



Neuland's R&D facility had been inspected by USDFA in February 2016 with zero observations

Significant R&D achievements

- Several NCE APIs added in NDA or commercial stage drugs
- Support for multiple APIs each year in Phase 2 and Phase 3 clinical candidates

Generic API business

- 978+ DMFs filed
- 300+ API processes developed
- 204+ patents filed
- 3 new DMFs filed in FY24
- 1 New DMF filed in Q1 FY25

Regulatory Filings



69

DMFs with
USFDA



32

Filings with
Health Canada



10

Japanese
DMF filed



17

China DMF
filed



20

Filings with
KFDA Korea



28

Filings with
TGA



274

ROW filings
including
Turkey, Mexico,
Brazil etc.



~499

EUDMF filings
across Germany,
France, Poland,
Italy etc.



29

CEPs received
for different
products



978+

Filings till date

**** The numbers on this slide reflect the number of filings, the number of active filings could vary as geographic filings are merged and changes in product portfolio**

Financial Highlights FY2015-2024



Rs. Cr

	FY2015	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Total Income	469.9	511.6	588.9	533.7	670.3	766.6	953.0	953.2	1,200.9	1,571.1
EBITDA	67.4	81.5	106.9	54.6	61.4	105.3	162.5	144.3	281.1	474.5
<i>EBITDA Margin</i>	<i>14.3%</i>	<i>15.9%</i>	<i>18.1%</i>	<i>10.2%</i>	<i>9.2%</i>	<i>13.7%</i>	<i>17.1%</i>	<i>15.1%</i>	<i>23.4%</i>	<i>30.2%</i>
PAT	15.8	26.4	46.4	11.8	16.1	15.9	80.3	63.5	163.1	299.6
<i>PAT Margin</i>	<i>3.4%</i>	<i>5.2%</i>	<i>7.9%</i>	<i>2.2%</i>	<i>2.4%</i>	<i>2.1%</i>	<i>8.4%</i>	<i>6.7%</i>	<i>13.6%</i>	<i>19.1%</i>
EPS	18.5	29.7	41.6	10.6	12.8	12.4	62.6	49.5	127.1	233.5
Current Ratio (x)	1.1	1.2	1.3	1.2	1.4	1.4	1.5	1.6	1.7	2.1
ROCE (%)	15.7%	18.4%	15.9%	5.0%	4.7%	8.9%	13.5%	9.7%	21.3%	32.8%
Fixed Asset Turnover (x)	3.8	3.7	3.8	3.2	2.9	2.3	2.4	2.1	2.7	3.1
Debt to Equity (x)	1.1	0.9	0.7	0.5	0.3	0.3	0.2	0.3	0.1	0.1

- Revenue was impacted in FY2018 as a result of mismatch in capacity vs orders. EBITDA margins in FY19 & FY20 were impacted as a result of spike in RM prices, which led Neuland to actively work towards Supply chain de-risking before the COVID19 pandemic
- ROCE was impacted by due to acquisition of unit III in FY2018 which was commercialized in FY2021. Unit 3 utilisation levels have recently started ramping up and momentum is expected to continue



Business Strategy

Neuland Strategy Framework



Strategic Priority - I

Build deep competency in complementary new technologies like bio-catalysis, flow chemistry, and physical properties, that are valued by our target customers and differentiated from competitors.

Strategic Priority - IV

Digitize planning to delivery processes, financial processes, customer servicing processes and build company-wide dashboard providing shared, real-time, granular data and analytics to create shared context across functions and improve the quality and speed of decisions at every level in the organization.

Strategic Priority - II

Optimize manufacturing capacity for agility, including flexible response to customer needs, multi-product production, and reserve capacity to respond quickly to customer needs.

Strategic Priority - V

Enable employee readiness to deliver on strategic business priorities.

Strategic Priority - III

Building project & client management capabilities which are transparent, flexible, focused on collaboration and constant customer feedback.

Strategic Priority - VI

GDS business that is focused on quality-conscious customers and pipeline products differentiated on technology.





Our Businesses

Generic APIs (GDS)



- We are a preferred service provider in the manufacturing of Active Pharmaceutical Ingredients (APIs)
- **Process Investigation Department (PID)** majorly helps our customers to meet their price pressures by way of cutting their total cost of ownership in developing an API thereby achieving excellence in Process development
- API manufacturing heritage of over 40 years
- Flexible 100g to hundreds of tons capacity
- Non-competitive advantage (does not compete in finished formulation)
- Worldwide customer base in 80+ countries
- Proven project management systems
- Impeccable EHS record



**Facilities &
Capacity**




Three US FDA and
cGMP compliant
manufacturing facilities

100 APIs across 10
diverse areas



Total capacity of the reactor volume
941,000 liters

CDMO Services (CMS)



Chemistry & manufacturing capabilities

Synthetic portion of fermented molecules

Deuterated molecules

Peptides in solid, solution phase & hybrid technology

Cyanation, hydrogenation, bromination, cryogenic

Steroidal bile acids & vitamin D derivatives

Carbohydrate chemistry

Cyclic and PEGylated peptides


Organometallic carbon-carbon bond formation

Heterocyclic compounds


Chiral compounds manufacturing



Facilities & Capacity



Three US FDA and cGMP compliant manufacturing facilities




Total capacity of the reactor volume
941,000 liters



Shareholder Information

Shareholding Details



Share Information (as on 30th September 2024)

NSE Ticker	NEULANDLAB
BSE Ticker	524558
Market Cap (Rs. Cr)	15,898
% free-float	67.36%
Free-float market cap (Rs. Cr)	10,709
Shares Outstanding	1,28,29,889
3M Average Daily Traded Volume (ADTV) (Shares)*	49,508
3M Average Daily Traded Value (In Rs. Cr)*	53.11
Industry	Pharmaceuticals

* Source: BSE & NSE



Annexure

Profit & Loss Snapshot (Standalone)





Particulars (Rs Cr)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	H1FY25	H1FY24	YoY (%)
Total Income	315.2	420.8	-25.1	444.4	-29.1%	759.6	785.8	-3.3%
EBITDA	65.7	140.3	-53.2	128.6	-48.9%	194.3	239.6	-18.9%
EBITDA Margin	20.8%	33.4%	-1260 bps	28.9%	-810 bps	25.6%	30.5%	-490 bps
Exceptional Item	-	-	-	20.6*	-	20.6*	-	-
Profit Before Tax*	48.5	121.4	-60.0%	130.3	-62.8%	178.8	204.9	-12.7%
PBT Margin	15.4%	28.9%	-1350 bps	29.3%	-1390 bps	23.5%	26.1%	-260 bps
Profit After Tax	32.0	89.1	-64.1%	98.3	-67.5%	130.3	151.3	-13.9%
PAT Margin	10.1%	21.2%	-1110 bps	22.1%	-1200 bps	17.2%	19.3%	-210 bps
EPS (Rs.)	24.9	69.4	-64.1%	76.6	-67.5 %	101.6	117.9	-13.9%

*Q1FY25 and H1FY25 includes exceptional item of profit on transfer of investment property of Rs. 20.6 crores

Revenue & PBT trend



Rs Cr



Sustainability Framework



Focus	Our Priorities	Our Commitments	Goal Area	Our Key Goals (included in our Executives' and Leaders' Balanced Scorecard)
 Environment	<ul style="list-style-type: none"> • Effluent and Waste^{3,4} • Water^{3,4} • Emissions and Climate Change^{3,4} • R&D and Innovation^{1,4} 	<ul style="list-style-type: none"> • Reduction in direct emissions • Efforts to water neutrality • Waste reduction • Reductions in indirect emissions • Sustainable R&D and Innovation 	Direct emissions (Scope 1 and 2)	<ul style="list-style-type: none"> • FY35: Carbon neutrality: 30%* reduction • FY50: Net Zero in absolute emissions (subject to residual – Approx 10%)*
			Water	<ul style="list-style-type: none"> • FY35: Achieve 25% water neutrality • FY50: Achieve 100% water neutrality
			Waste	<ul style="list-style-type: none"> • Maintain Zero Waste to Landfill • 100% co-processing of waste • Maintain Zero Liquid Discharge status of effluents
			Indirect emissions (Scope 3)	<ul style="list-style-type: none"> • FY35: 10%* reduction in indirect carbon emissions (including logistics)
 Social	<ul style="list-style-type: none"> • Occupational Health and Safety^{3,4} • Human Capital Development^{3,4,5} • Community well-being^{3,5} 	<ul style="list-style-type: none"> • Zero Harm • People well-being and development • Human Rights • Improve Diversity • ESG Awareness and capability building 	Zero Harm	<ul style="list-style-type: none"> • Maintain Zero Fatality • Maintain Nil LTIFR
			People diversity	FY30: <ul style="list-style-type: none"> • 10% Women in Management Positions • 16% of all hirings will be Women • 0.5% of all employees will be PwD and Other Genders (LGBTQIA+)
 Governance	<ul style="list-style-type: none"> • Compliance^{3,5} • Business Continuity and disaster recovery^{1,2} • Digitalisation² • Sustainable Supply Chain^{2,5} 	<ul style="list-style-type: none"> • Ethics and Compliance • Excellence in Corporate Governance • Risk and Crisis Management Capability • Integrity in reporting • Sustainable supply chain 	Sustainable supply chain	FY25: Create a roadmap for sustainable supply chain with key milestones

*Aligning ESG priorities with our values: [1] Customer Centricity → [2] Reliability → [3] Accountability → [4] Ownership → [5] Openness and transparency

Glossary



Term	Description
Active Pharmaceutical Ingredient (API)	Any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body
Biologic	Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues.
Commercial molecules	Molecules where Neuland is manufacturing for commercial use after the product has been approved
Custom Manufacturing Solutions (CMS)/ Contract Development and Manufacturing Organization (CDMO)	Develop and manufacture pharmaceutical ingredients and intermediates in line with customer expectations.
Development Molecules	Projects where Phase-3 is over, and molecules have been filed but not yet commercial.
DMF	A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs
GDS	Generic Drug Substance (GDS) segment which includes Prime products and Specialty products
International Council for Harmonisation (ICH) Guidelines	Harmonisation project involving regulatory authorities and pharmaceutical industry to improve efficiency of new drug development and registration processes
New Chemical Entity (NCE)	NCE is granted to “a drug that contains no active moiety that has been approved by FDA in any other application”
Peptides	Peptides are sequences of molecules called amino acids. Peptides of precise sequences may occur naturally in the body, but they may also be produced synthetically or using recombinant DNA technology in bacteria and other living systems. These molecules are used to treat a variety of diseases

Term	Description
Pipeline drugs	Drugs (small or large molecule) under development by a manufacturer
Prime APIs	The prime products which typically include mature APIs with relatively higher competition in API space have historically contributed more than 70% of the total business.
Specialty/ Niche APIs	Molecules in the API space which are complex in nature and are in the nature of ‘high value’ added products and Neuland’s focus has been to develop these molecules from laboratory scale to large commercial quantities
Preclinical study	Preclinical studies take place in animals before any testing in humans is done.
Phase I clinical trial	Researchers test an experimental drug or treatment in a small group of people for the first time.
Phase II clinical trial	The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase III clinical trial	The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.
Small molecule products	A drug that can enter cells easily because it has a low molecular weight. Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. This is different from drugs that have a large molecular weight, which keeps them from getting inside cells easily. Many targeted therapies are small-molecule drugs
USFDA	The US Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices



Thank you

For further information contact

IR Desk
Neuland Labs
Contact: +91 40 6761 1600
Email: mir@Neulandlabs.com

Ravi Udeshi / Minakshi Machutre
EY IR
Contact: +91 22 6192 2000
Email: Ravi.udeshi@in.ey.com / Minakshi.Machutre@in.ey.com